Adherium Limited (ASX: ADR) - Share Price
- Current share price for ADR : $0.070
Adherium Limited (ADR) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a provider of integrated digital health solutions and connected respiratory medical devices. Adherium's Hailie platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.
ADR General Information +
| ASX Code | ADR |
| Website | N/A |
| Industry/Sector | Health Care Technology |
| Market Cap ($M) | 3 |
| ADR Share Price | $0.070 |
| Day High | $0.000 |
| Day Low | $0.000 |
| Last Close | $0.070 |
| ADR Share Price Movement | - ( No change ) |
Prices as at 16:40, 21 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Adherium Limited (ADR) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| HFResult | 3.25¢ | 100% | 15 Sep 2016 | 4 Oct 2016 | - | - | - |
| Result | 1.25¢ | 100% | 23 Mar 2016 | 7 Apr 2016 | - | - | - |
See all dividends from Adherium Limited (ADR) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Adherium Limited (ADR) price-sensitive announcements
ADR - Preliminary Final Report
Adherium Limited’s Appendix 4E Preliminary Final Report for the financial year ended 30 Ju
Adherium Limited (ADR)
31 Aug 2026 | 7:07 PM
31 Aug 2026 | 7:07 PM
ADR - Adherium enters into additional $1M short-term loan facility
Adherium Limited has secured an additional AUD $1 million short-term unsecured loan facili
Adherium Limited (ADR)
18 Aug 2026 | 8:57 AM
18 Aug 2026 | 8:57 AM
ADR - Adherium Announces CEO Transition
Adherium Limited, a leader in digital respiratory management, announced the transition of
Adherium Limited (ADR)
29 Jul 2026 | 12:06 PM
29 Jul 2026 | 12:06 PM
ADR - Quarterly Activities/Appendix 4C Cash Flow Report
Adherium Limited reported its Appendix 4C Quarterly Cash Flow for the quarter ending 30 Ju
Adherium Limited (ADR)
29 Jul 2026 | 8:29 AM
29 Jul 2026 | 8:29 AM
Adherium Limited (ADR) Recent ASX Announcements
ADR Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$14.16 | -$0.30 | -99.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$12.68 | -$139.90 | -29.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$10.22 | -$198.30 | -20.30% | 0.00 | 0.00 | 0.00% | 0.0% |
ADR Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| 4DMedical Limited (4DX) | $2,246M | 1.7823 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Adherium Limited (ADR) | $4M | -0.9981 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Artrya Limited (AYA) | $416M | -0.0450 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Pro Medicus Limited (PME) | $18,797M | 1.3034 | -0.2811 | 0.2395 | 70.9503 | 98.6945 | 79.6221 | 0.38% | 0.51% | 0.64% |
ADR Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Louis (Lou) James Panaccio | Non-Executive Director | 25 Feb 2022 |
| Mr Jeremy Curnock-Cook | Non-Executive Director | 17 Apr 2015 |
| Mr Keven Gessner | Non-Executive Director | 8 May 2025 |
| Ms Victoria Durrans | Non-Executive Director | 1 Jun 2026 |
| Mr George Baran | Non-Executive Director, Non-Executive Chairman | 13 May 2021 |
Adherium Limited (ADR) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 22 Jun 2026 | BARAN, George | Issued | Indirect Shares | 105,331,536 | $0.003 | $315,994.608 |
| 22 Jun 2026 | PANACCIO, Louis (Lou) | Issued | Indirect Shares | 9,666,664 | $0.003 | $28,999.992 |
| 20 Mar 2026 | BARAN, George | Issued | Indirect Shares | 22,371,011 | $0.005 | $111,855.055 |
See all changes in directors' interest & trades for Adherium Limited (ADR) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ADR Management
| Name | Position |
|---|---|
| John Perry | Interim CEO |
| Priyamvada Sanjay Rasal (Pia) | Joint Company Secretary |
| Anvi Mehta | Joint Company Secretary |
ADR Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Adherium Limited (ADR). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 364,651,488 (19.57%) | Regal Funds Management Pty Limited |
| 343,776,885 (18.45%) | Trudell Medical Limited |
| 343,770,320 (18.45%) | Phillip Asset Management Ltd |
| 208,172,938 (11.17%) | UBS Group AG and its related bodies corporate |
| 125,168,715 (6.72%) | Bank of America Corporation and its related bodies corporate |
| 106,836,248 (5.73%) | K One W One Limited |
ADR Calendar of Events
| Date | Event |
|---|---|
| 29 September 2027 | Report (Annual) |
| 30 August 2027 | Report (Prelim) |
| 26 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
